Long-Term Outcome of Merkel Cell Carcinoma After Avelumab

From General Health Surveillance to Targeted Occupational Risk Assessment

For decades, public health communication in the mass production sector has centered on general wellness principles—emphasizing hygiene, vaccination, and early symptom awareness. This foundational approach successfully reduced communicable disease burdens and improved baseline health literacy among workers. However, as industrial environments evolve, so too must the scope of occupational health surveillance. The same populations that benefited from broad-spectrum health guidance now face emerging exposures tied to advanced manufacturing processes. Specifically, workers in facilities handling biologic agents or immunomodulatory compounds may encounter substances with long-term oncologic implications. One such area of growing concern involves exposure to agents that influence immune checkpoint pathways, particularly in settings where Avelumab—a monoclonal antibody targeting PD-L1—is manufactured or administered. While Avelumab itself is a therapeutic intervention, its production and handling raise questions about unintended occupational contact. This shifts the focus from general health promotion to a more targeted inquiry: what are the long-term outcomes for individuals who develop Merkel cell carcinoma following potential workplace exposure to such immunomodulatory agents? Understanding prognosis in this context requires moving beyond population-level health messaging toward individualized risk assessment, where the legacy of general health education must now accommodate the complexities of occupational carcinogen surveillance and post-exposure monitoring.

Avelumab and Merkel Cell Carcinoma: Clinical Evidence and Mechanisms

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096). It was the first therapeutic agent specifically approved for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096; https://pubmed.ncbi.nlm.nih.gov/33439294). Approval was based on the two-part, single-arm phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096). Immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381). However, despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101). Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101). The disease carries high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101). Clinical presentation typically involves a rapidly growing, painless, firm, red or purple nodule on sun-exposed skin, often in older individuals. Diagnosis is confirmed by histopathology and immunohistochemistry, with characteristic neuroendocrine markers such as cytokeratin 20 and chromogranin A. Avelumab's pharmacology involves blockade of PD-L1, which prevents the interaction with PD-1 on T cells, thereby restoring antitumor immune responses. This mechanism can lead to overactivation of the immune system, resulting in immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781). Reported adverse effects include a range of irAEs such as pneumonitis, colitis, hepatitis, endocrinopathies, and dermatologic reactions. A case report described hypercalcemia due to reactivation of sarcoidosis during avelumab treatment for metastatic MCC, which was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781). This highlights the need for vigilance regarding atypical irAEs.

Prognosis and Long-Term Outcomes After Avelumab Therapy

For patients who become refractory to avelumab, treatment options are limited. In Europe, approved systemic therapies are restricted to avelumab (https://pubmed.ncbi.nlm.nih.gov/33439294). For avelumab-refractory patients, combined ipilimumab plus nivolumab (IPI/NIVO) has shown activity. In a retrospective study at three German academic sites, three out of five patients with metastatic MCC refractory to avelumab responded to combined IPI/NIVO according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294). A multicenter study from the prospective skin cancer registry ADOREG further supports the use of ipilimumab plus nivolumab in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381). A separate retrospective study noted that immune checkpoint inhibitors, including avelumab, offer durable responses and significant clinical benefit, but approximately 50% of patients with advanced MCC progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101). Prognosis-related considerations for affected patients are critical. The long-term outcome of MCC after avelumab treatment depends on several factors, including the initial response to therapy, the development of resistance, and the management of adverse effects. While avelumab can induce durable responses in a subset of patients, the high rate of progression (approximately 50%) underscores the need for effective second-line therapies. The timeline between exposure to avelumab and documented harm varies. Immune-related adverse events can occur at any time during treatment, sometimes after several cycles, as seen in the sarcoidosis case where hypercalcemia developed during ongoing therapy (https://pubmed.ncbi.nlm.nih.gov/31543781). For patients who progress, the timeline to progression can be months to years, and the subsequent response to salvage therapy like IPI/NIVO may be rapid, as observed in the retrospective studies. Adequacy of warnings regarding avelumab and MCC is an important risk anchor. The prescribing information for avelumab includes warnings about immune-mediated adverse reactions, but the specific risk of hypercalcemia due to sarcoidosis reactivation may not be prominently highlighted. Clinicians should be aware of this potential complication, especially in patients with a history of sarcoidosis or other granulomatous diseases. Additionally, the lack of approved therapies for avelumab-refractory disease in Europe emphasizes the need for clear communication about the possibility of progression and the limited subsequent options. The evidence suggests that while avelumab is a valuable first-line immunotherapy for metastatic MCC, its long-term efficacy is constrained by primary and acquired resistance, and patients should be counseled about the potential need for alternative treatments. In summary, avelumab provides a meaningful therapeutic option for metastatic MCC, with objective response rates around one-third in chemotherapy-refractory patients. However, the aggressive nature of MCC, the high rate of progression, and the potential for immune-related adverse events necessitate careful monitoring and proactive management. For patients who progress on avelumab, combined ipilimumab plus nivolumab offers a salvage strategy, though data are limited to small retrospective series. The long-term prognosis remains guarded, and ongoing research is needed to improve outcomes for this rare but deadly cancer.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the long-term prognosis for Merkel cell carcinoma after treatment with avelumab?

The long-term prognosis for Merkel cell carcinoma (MCC) after avelumab treatment is variable. While avelumab can induce durable responses in about one-third of patients with chemotherapy-refractory metastatic MCC, approximately 50% of patients with advanced MCC progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101). Factors influencing prognosis include initial response, development of resistance, and management of immune-related adverse events. For those who progress, salvage therapy with ipilimumab plus nivolumab may be effective, but data are limited to small retrospective studies (https://pubmed.ncbi.nlm.nih.gov/33439294). Overall, the prognosis remains guarded due to the aggressive nature of MCC.

What are the common immune-related adverse events associated with avelumab in MCC patients?

Avelumab can cause immune-related adverse events (irAEs) due to its mechanism of blocking PD-L1, leading to overactivation of the immune system. Common irAEs include pneumonitis, colitis, hepatitis, endocrinopathies, and dermatologic reactions (https://pubmed.ncbi.nlm.nih.gov/31543781). A case report also described hypercalcemia due to reactivation of sarcoidosis during avelumab treatment, which was managed with corticosteroids (https://pubmed.ncbi.nlm.nih.gov/31543781). Clinicians should monitor for both typical and atypical irAEs throughout treatment.

What treatment options are available for MCC patients who progress on avelumab?

For patients with metastatic MCC who become refractory to avelumab, treatment options are limited, especially in Europe where avelumab is the only approved systemic therapy (https://pubmed.ncbi.nlm.nih.gov/33439294). However, combined ipilimumab plus nivolumab (IPI/NIVO) has shown activity in avelumab-refractory patients. In a retrospective study, three out of five patients responded to IPI/NIVO (https://pubmed.ncbi.nlm.nih.gov/33439294), and a multicenter registry study supports its use (https://pubmed.ncbi.nlm.nih.gov/36450381). These data are from small series, and further research is needed.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel cell carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.